MIV Therapeutics Inc.

EANS-News: MIV Therapeutics Inc.

  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.

Richmond BC (euro adhoc) - April 30, 2012, Vancouver, British Columbia (OTC
Pinks: MIVI) MIV Therapeutics, Inc. (the "Company" or "MIV") announced that MIV
finalize the arrangement of payment with Purple Medical Solution of India for
the sale of MIV India division, in which accordingly to the fifth amended Sale
and Purchase Agreement between the two parties, Purple Medial Solution will
settle the outstanding balance by monthly payment before Oct 2012, with
immediate effect. 
Furthermore,the two parties will continue to endeavor to a new structure in
order to inject an operating stent manufacturer with significant revenue and
profit as major shareholder of current MIV Therapeutics, and MIV will develop
further market expansion as well as CE marking accreditation for the best
interest of all shareholders.  
MIV has also engaged one of the leading IR companies Euro Ad Hoc as its agent in
Europe to facilitate the investors relationship as part of MIV's further
marketing and branding process as part of the strategic plan. 

About MIV Therapeutics, Inc.

MIV Therapeutics, Inc. is a development stage company in the business of
developing next-generation coatings and drug-delivery systems for cardiovascular
stents and other implantable medical devices.

Safe Harbour Statements

Except for the statements of historical fact contained herein, the information
presented in this news release constitutes "forward-looking statements" as such
term is used in applicable United States and Canadian laws. These statements
relate to analyses and other information that are based on forecasts of future
results, estimates of amounts not yet determinable and assumptions of
management. Any statements that express or involve discussions with respect to
predictions, expectations, beliefs, plans, projections, objectives, assumptions
or future events or performance (often, but not always, using words or phrases
such as "expects" or "does not expect", "is expected", "anticipates" or "does
not anticipate", "plans, "estimates" or "intends", or stating that certain
actions, events or results "may", "could", "would", "might" or "will" be taken,
occur or be achieved) are not statements of historical fact and should be viewed
as "forward-looking statements". Such forward looking statements involve known
and unknown risks, uncertainties and other factors which may cause the actual
results, performance or achievements of the Company to be materially different
from any future results, performance or achievements expressed or implied by
such forward-looking statements. 

Forward looking statements are made based on management's beliefs, estimates and
opinions on the date the statements are made and the Company undertakes no
obligation to update forward-looking statements if these beliefs, estimates and
opinions or other circumstances should change, except as required by applicable
law. Although the Company believes that the beliefs, plans, expectations and
intentions contained in this news release are reasonable, there can be no
assurance those beliefs, plans, expectations or intentions will prove to be
accurate.  Such forward-looking statements reflect our current views with
respect to future events and are subject to certain risks, uncertainties and
assumptions, including, the risks and uncertainties outlined in our most recent
financial statements and reports filed with the United States Securities and
Exchange Commission (the "SEC") (available at www.sec.gov) and with Canadian
securities administrators (available at www.sedar.com).  Investors should
consider all of the information set forth herein and should also refer to the
risk factors disclosed in the Company's periodic reports filed from time-to-time
with the SEC. The Company again cautions investors that the Company is not
up-to-date in its SEC or SEDAR filings.  Pink OTC Markets has discontinued the
display of quotes on otcmarkets.com for the Company's securities because the
Company's securities have been labeled Caveat Emptor (Buyer Beware) and because
adequate current information has not been made available by the Company.

This news release shall not constitute an offer to sell or the solicitation of
an offer to buy securities of the Company nor shall there be any sale of these
securities in any jurisdiction in which such offer, solicitation or sale would
be unlawful prior to registration or qualification under the securities laws of
any such jurisdiction.

MIV Therapeutics, Inc.
Fax:  +1 604 357 1640

Further inquiry note:
Fax: +1 604 357 1640

end of announcement                               euro adhoc 

company:     MIV Therapeutics Inc.
             Viking Way #250-4320 
             CA-V6V2L4 Richmond BC
FAX:         +1 604 357 1640
sector:      Pharmaceuticals
ISIN:        US55306V2051
stockmarkets: free trade: Stuttgart 
language:   English

Weitere Meldungen: MIV Therapeutics Inc.

Das könnte Sie auch interessieren: